[Progress of clinical trials in Alzheimer’s disease drugs]

Area of Science:

• Neuroscience
• Pharmacology
• Drug Discovery

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder with unclear pathogenesis and no cure.
• Current AD treatments only manage cognitive symptoms, failing to halt disease progression.
• Neuronal loss in the cortex and hippocampus characterizes AD progression.

Purpose of the Study:

• To summarize early-phase clinical trial interventions for Alzheimer's disease.
• To explore novel therapeutic strategies for AD, including multi-target approaches and neurogenesis induction.
• To highlight the potential of natural products in AD treatment development.

Main Methods:

• Review of early-phase clinical trials for Alzheimer's disease interventions.
• Analysis of therapeutic strategies targeting multiple pathways in AD.
• Investigation of small molecule compounds and natural products for neurogenesis induction.

Main Results:

• Complex diseases like AD may require multi-target or cocktail drug therapies.
• Inducing neurogenesis is a potential therapeutic avenue for AD.
• Natural products from China show significant pharmacological effects on multi-targets and neurogenic activity.

Conclusions:

• Developing effective Alzheimer's disease treatments necessitates innovative strategies beyond single-target interventions.
• Multi-target drugs and therapies promoting neurogenesis, particularly those derived from natural products, represent a promising frontier for future AD drug development.